TY - JOUR T1 - Prevalence, incidence, and characteristics of chronic cough among adults from the Canadian Longitudinal Study on Ageing (CLSA) JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00160-2021 SP - 00160-2021 AU - Imran Satia AU - Alexandra J. Mayhew AU - Nazmul Sohel AU - Om Kurmi AU - Kieran J. Killian AU - Paul M. O'Byrne AU - Parminder Raina Y1 - 2021/01/01 UR - http://openres.ersjournals.com/content/early/2021/03/11/23120541.00160-2021.abstract N2 - The global prevalence of chronic cough(CC) is highly variable ranging from 2–18%. There is a lack of data on the prevalence and incidence of CC from the general population. The objective of this study was to investigate the prevalence and incidence of CC in a sample of Canadian adults, and how these influenced by age, sex, smoking, respiratory symptoms, medical co-morbidities, and lung function.Participants with chronic cough were identified from the Canadian Longitudinal Study on Ageing (CLSA) based on a self-reported daily cough in the last 12 months. This is a prospective, nationally generalisable, stratified random sample of adults aged 45–85 at baseline recruited between 2011–2015, and followed-up 3 years later. The prevalence and incidence per-100-person-years are described, with adjustments for age, sex and smoking.Of the 30 097 participants, 29 972 completed the CC question at baseline and 26 701 at follow-up. The prevalence of CC was 15.8% at baseline and 17.6% at follow-up with 10.4%–17.1% variation across 7 provinces included in the CLSA comprehensive sample. Prevalence increased with age, current smoking, and was higher in males(15.2%), Caucasians(14%), and those born in North America, Europe or Oceania(14%). The incidence of CC adjusted for age, sex and smoking was higher in males, underweight and obese. Respiratory symptoms, airways diseases, lower FEV1%predicted, cardio-vascular diseases, psychological disorders, diabetes and chronic pain had a higher incidence of CC.The prevalence and incidence of CC is high in the CLSA sample with geographic, ethnic and gender differences which is influence by a number of medical co-morbidities.FootnotesThis manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.Conflict of interest: Dr. Satia reports grants and personal fees from Merck, during the conduct of the study; personal fees from Educational Talks for GPs; GSK, Astrazeneca, grants and personal fees from Merck Canada, grants from ERS Respire 3 Marie Curie Fellowship, grants from E..J. Moran Campbell Early Career Award, outside the submitted work; .Dr. Satia reports personal fees from Educational Talks for GPs; GSK, Astrazeneca, grants and personal fees from Merck Canada, grants from ERS Respire 3 Marie Curie Fellowship, outside the submitted work; .Dr. Satia reports grants and personal fees from Merck, during the conduct of the study; personal fees from Educational Talks for GPs; GSK, Astrazeneca, grants from ERS Respire 3 Marie Curie Fellowship, grants from E..J. Moran Campbell Early Career Award, outside the submitted work.Conflict of interest: Dr. Mayhew has nothing to disclose.Conflict of interest: Dr. Nazmul has nothing to disclose.Conflict of interest: Dr. Kurmi has nothing to disclose.Conflict of interest: Dr. Killian has nothing to disclose.Conflict of interest: Dr. O'Byrne reports grants and personal fees from AstraZeneca, personal fees from GSK, grants from Novartis, grants and personal fees from Medimmune, personal fees from Chiesi, outside the submitted workConflic of interest: Dr. Raina has nothing to disclose. ER -